PP
GYRE icon

PDT Partners’s Gyre Therapeutics GYRE Stock Holding History

PDT Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,875
Closed -$89K – 931
2021
Q3 		$89K Buy
2,875
+1,302
+83% +$42.8K 0.01% 738
2021
Q2 		$51K Sell
1,573
-5,760
-79% -$198K ﹤0.01% 773
2021
Q1 		$277K Buy
7,333
+2,693
+58% +$123K 0.02% 636
2020
Q4 		$220K Sell
4,640
-841
-15% -$36.4K 0.01% 601
2020
Q3 		$177K Buy
5,481
+2,561
+88% +$100K 0.01% 642
2020
Q2 		$129K Sell
2,920
-273
-9% -$12.8K 0.01% 619
2020
Q1 		$105K Buy
3,193
+1,633
+105% +$75K 0.01% 611
2019
Q4 		$80K Sell
1,560
-2,160
-58% -$90.5K ﹤0.01% 697
2019
Q3 		$137K Hold
3,720
– – 0.01% 426
2019
Q2 		$206K Buy
+3,720
New +$232K 0.01% 364
2015
Q3 		– Sell
-13
Closed -$28K – 1389
2015
Q2 		$28K Hold
13
– – ﹤0.01% 1311
2015
Q1 		$30K Hold
13
– – ﹤0.01% 1343
2014
Q4 		$27K Sell
13
-7
-35% -$13.5K ﹤0.01% 604
2014
Q3 		$40K Hold
20
– – ﹤0.01% 1257
2014
Q2 		$71K Buy
20
+4
+25% +$13.1K ﹤0.01% 1376
2014
Q1 		$60K Hold
16
– – ﹤0.01% 1287
2013
Q4 		$53K Buy
16
+3
+23% +$11.8K 0.01% 615
2013
Q3 		$54K Buy
+13
New +$52.3K ﹤0.01% 1464

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PDT Partners's GYRE Position: Q4 2021 in Review

PDT Partners sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 2,875 shares — an estimated $89K sold.

PDT Partners first reported a position in GYRE in Q3 2013 and held it in 18 quarters. The position peaked at $277K in Q1 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • PDT Partners reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 2,875 Gyre Therapeutics shares in Q4 2021, an estimated $89K.
  • PDT Partners first reported a position in Gyre Therapeutics in Q3 2013 and held it in 18 quarters.
  • PDT Partners's Gyre Therapeutics position peaked at $277K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.